Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.43
(-0.08%)
AUD 12.43
(-0.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 157.08 Million AUD | 85270.11% |
| 2022 | 184 Thousand AUD | 102.36% |
| 2021 | -7.79 Million AUD | 15.22% |
| 2020 | -9.19 Million AUD | 15.01% |
| 2019 | -10.81 Million AUD | -451.97% |
| 2018 | 3.07 Million AUD | -6.54% |
| 2017 | 3.28 Million AUD | 127.37% |
| 2016 | -12.01 Million AUD | 10.32% |
| 2015 | -13.39 Million AUD | -61.47% |
| 2014 | -8.29 Million AUD | 26.57% |
| 2013 | -11.29 Million AUD | -121.82% |
| 2012 | -5.09 Million AUD | -9.53% |
| 2011 | -4.65 Million AUD | 4.96% |
| 2010 | -4.89 Million AUD | -5014.85% |
| 2009 | 99.56 Thousand AUD | 100.65% |
| 2008 | -15.41 Million AUD | -26.88% |
| 2007 | -12.15 Million AUD | -20.13% |
| 2006 | -10.11 Million AUD | -21.75% |
| 2005 | -8.3 Million AUD | -45.91% |
| 2004 | -5.69 Million AUD | -0.83% |
| 2003 | -5.64 Million AUD | -3.46% |
| 2002 | -5.45 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 8.01 Million AUD | 0.0% |
| 2023 Q2 | 47.8 Million AUD | 0.0% |
| 2023 FY | 157.08 Million AUD | 85270.11% |
| 2023 Q4 | 109.27 Million AUD | 0.0% |
| 2022 Q4 | 7.23 Million AUD | 0.0% |
| 2022 FY | 184 Thousand AUD | 102.36% |
| 2022 Q2 | -7.05 Million AUD | 0.0% |
| 2021 Q2 | -7.96 Million AUD | 0.0% |
| 2021 FY | -7.79 Million AUD | 15.22% |
| 2021 Q4 | 170 Thousand AUD | 0.0% |
| 2020 FY | -9.19 Million AUD | 15.01% |
| 2020 Q2 | -4.76 Million AUD | 0.0% |
| 2020 Q4 | -4.43 Million AUD | 0.0% |
| 2019 FY | -10.81 Million AUD | -451.97% |
| 2019 Q2 | -7.88 Million AUD | 0.0% |
| 2019 Q4 | -2.93 Million AUD | 0.0% |
| 2018 Q4 | 7.16 Million AUD | 0.0% |
| 2018 FY | 3.07 Million AUD | -6.54% |
| 2018 Q2 | -4.09 Million AUD | 0.0% |
| 2017 Q2 | -3.55 Million AUD | 0.0% |
| 2017 Q4 | 6.84 Million AUD | 0.0% |
| 2017 FY | 3.28 Million AUD | 127.37% |
| 2016 Q2 | -7.37 Million AUD | 0.0% |
| 2016 FY | -12.01 Million AUD | 10.32% |
| 2016 Q4 | -4.63 Million AUD | 0.0% |
| 2015 Q4 | -8.04 Million AUD | 0.0% |
| 2015 FY | -13.39 Million AUD | -61.47% |
| 2015 Q2 | -5.34 Million AUD | 0.0% |
| 2014 Q2 | -4.65 Million AUD | 0.0% |
| 2014 Q4 | -3.64 Million AUD | 0.0% |
| 2014 FY | -8.29 Million AUD | 26.57% |
| 2013 Q4 | -7.37 Million AUD | -161.05% |
| 2013 FY | -11.29 Million AUD | -121.82% |
| 2013 Q3 | -2.82 Million AUD | 7.75% |
| 2013 Q2 | -3.06 Million AUD | -8.4% |
| 2013 Q1 | -2.82 Million AUD | 0.0% |
| 2012 Q2 | -1.27 Million AUD | 0.0% |
| 2012 Q3 | -1.27 Million AUD | 0.0% |
| 2012 FY | -5.09 Million AUD | -9.53% |
| 2012 Q4 | -2.82 Million AUD | -121.82% |
| 2012 Q1 | -1.27 Million AUD | 0.0% |
| 2011 Q3 | -1.18 Million AUD | 0.0% |
| 2011 Q1 | -1.18 Million AUD | 0.0% |
| 2011 Q2 | -1.18 Million AUD | 0.0% |
| 2011 FY | -4.65 Million AUD | 4.96% |
| 2011 Q4 | -1.27 Million AUD | -7.3% |
| 2010 Q3 | -1.24 Million AUD | 0.0% |
| 2010 Q1 | -1.24 Million AUD | 0.0% |
| 2010 Q4 | -1.18 Million AUD | 4.91% |
| 2010 FY | -4.89 Million AUD | -5014.85% |
| 2010 Q2 | -1.24 Million AUD | 0.0% |
| 2009 Q2 | -7285.09 AUD | 0.0% |
| 2009 Q4 | -1.24 Million AUD | -17030.98% |
| 2009 Q1 | -7285.09 AUD | 0.0% |
| 2009 Q3 | -7285.09 AUD | 0.0% |
| 2009 FY | 99.56 Thousand AUD | 100.65% |
| 2008 Q2 | -3.85 Million AUD | 0.0% |
| 2008 Q3 | -3.85 Million AUD | 0.0% |
| 2008 Q4 | -7285.09 AUD | 99.81% |
| 2008 FY | -15.41 Million AUD | -26.88% |
| 2008 Q1 | -3.85 Million AUD | 0.0% |
| 2007 Q3 | -3.05 Million AUD | 0.0% |
| 2007 Q1 | -3.05 Million AUD | 0.0% |
| 2007 FY | -12.15 Million AUD | -20.13% |
| 2007 Q4 | -3.85 Million AUD | -26.25% |
| 2007 Q2 | -3.05 Million AUD | 0.0% |
| 2006 Q4 | -3.05 Million AUD | -20.73% |
| 2006 Q3 | -2.52 Million AUD | 0.0% |
| 2006 FY | -10.11 Million AUD | -21.75% |
| 2006 Q1 | -2.52 Million AUD | 0.0% |
| 2006 Q2 | -2.52 Million AUD | 0.0% |
| 2005 Q1 | -2.07 Million AUD | 0.0% |
| 2005 Q2 | -2.07 Million AUD | 0.0% |
| 2005 Q3 | -2.07 Million AUD | 0.0% |
| 2005 Q4 | -2.52 Million AUD | -21.75% |
| 2005 FY | -8.3 Million AUD | -45.91% |
| 2004 Q2 | - AUD | 0.0% |
| 2004 FY | -5.69 Million AUD | -0.83% |
| 2004 Q4 | -2.07 Million AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2004 Q3 | - AUD | 0.0% |
| 2003 Q1 | - AUD | 0.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 FY | -5.64 Million AUD | -3.46% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 Q2 | - AUD | 0.0% |
| 2002 FY | -5.45 Million AUD | 0.0% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 Q2 | - AUD | 0.0% |
| 2002 Q3 | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 3019.033% |
| Acrux Limited | -5.8 Million AUD | 2808.293% |
| Amplia Therapeutics Limited | -4.5 Million AUD | 3588.012% |
| Biome Australia Limited | -1.67 Million AUD | 9504.91% |
| BTC Health Limited | 1.05 Million AUD | -14785.145% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 1353.654% |
| CSL Limited | 2.64 Billion AUD | 94.054% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 471.136% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | -340.789% |
| Noxopharm Limited | -3.57 Million AUD | 4490.046% |
| PharmAust Limited | -9.03 Million AUD | 1839.092% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 2563.545% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 2006.774% |
| PYC Therapeutics Limited | -37.72 Million AUD | 516.38% |
| Race Oncology Limited | -13.81 Million AUD | 1236.675% |
| Starpharma Holdings Limited | -8.16 Million AUD | 2023.834% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | -2155.457% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 1232.547% |
| Memphasys Limited | -4.44 Million AUD | 3636.251% |
| Nyrada Inc. | -1.38 Million AUD | 11431.55% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 10923.901% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | -2914.412% |
| Bio-Gene Technology Limited | -2.4 Million AUD | 6620.105% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 529.548% |
| Patrys Limited | -3.53 Million AUD | 4538.382% |
| Dimerix Limited | -17.07 Million AUD | 1019.943% |
| Orthocell Limited | -7.18 Million AUD | 2287.465% |
| Imugene Limited | -149.68 Million AUD | 204.944% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 1711.962% |
| Immutep Limited | -39.89 Million AUD | 493.723% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 1896.025% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 921.405% |
| Nanollose Limited | -1.15 Million AUD | 13681.825% |
| Invex Therapeutics Ltd | -1.64 Million AUD | 9667.556% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | -48350.387% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | 5584.063% |
| Biotron Limited | -3.43 Million AUD | 4670.927% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 427.599% |
| Tissue Repair Ltd | -4.13 Million AUD | 3895.965% |
| AnteoTech Limited | -8.88 Million AUD | 1868.827% |
| Hexima Limited | -933.87 Thousand AUD | 16920.381% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 367.813% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 989.387% |
| Avecho Biotechnology Limited | -3.43 Million AUD | 4670.878% |
| Actinogen Medical Limited | -13.04 Million AUD | 1304.213% |
| Immuron Limited | -6.93 Million AUD | 2364.408% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 2966.709% |